Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain
The present application is directed to stabilized envelope glycoprotein trimers. The trimers are stabilized by introducing disulfide bonds at certain sites in the gp41 ectodomain. DNA molecules encoding such trimers can be used to generate an immunogenic reaction.
1. An isolated molecule containing a nucleotide sequence encoding an HIV-1 or HIV-2 envelope glycoprotein containing at least:
i) a coiled coil portion of a gp41 transmembrane glycoprotein, wherein said coiled coil has a heptad repeat wherein each of said seven consecutive amino acid residues are designated a, b, c, d, e, f, and g corresponding to amino acid sequences selected from a group consisting of amino acids 555–561, 562–568, 569–575, 576–582 and 583–589 of SEQ ID NO: 11, wherein at least two amino acids in positions “a”, “d” and “e” have been substituted by cysteine residues, and “f” is glycine; and
ii) a gp120 glycoprotein or gp120 derivative, wherein the gp120 derivative contains multiple gp120 constant regions connected by variable regions and/or linker residues that permit potential turns in the polypeptide structure so that the derivative maintains a conformation approximating that of wild type gp120, wherein at least a portion of one variable region has been deleted.
2. The isolated molecule of claim 1 wherein the gp120 glycoprotein or derivative is the gp120 derivative.
3. The isolated molecule of claim 2 , wherein the gp120 derivative lacks portions of at least the V1, V2, C1 and/or C5 regions.
4. The isolated molecule of claim 3 , wherein the gp120 derivative is a HIV-1 gp120 derivative.
5. The isolated molecule of claim 1 , wherein the nucleotide sequence is a DNA sequence.
6. A vector containing the nucleotide sequence of claim 1 operably linked to a promoter.
7. The vector of claim 6 , wherein the vector is a viral vector.
8. A pharmaceutical composition containing (a) the purified protein encoded by the nucleotide sequence of claim 1 or a nucleotide molecule encoding said purified protein, and (b) a pharmaceutically acceptable carrier or diluent.
9. A method of generating an immune reaction comprising administering an immunogen-stimulating amount of the protein encoded by the nucleotide sequence of claim 1 and an adjuvant to an animal.
10. A method of generating an immune reaction comprising
administering an immunogen-stimulating amount of the DNA sequence of claim 1 .